Evripidis Lanitis
Overview
Explore the profile of Evripidis Lanitis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
1707
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kosti P, Abram-Saliba J, Pericou-Troquier L, Pavelot S, Ruggeri T, Laffaille M, et al.
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40081946
Background: The glycosylphosphatidylinositol-anchored cell surface protein mesothelin (MSLN) shows elevated expression in many malignancies and is an established clinical-stage target for antibody-directed therapeutic strategies. Of these, the harnessing of autologous...
2.
Corria-Osorio J, Carmona S, Stefanidis E, Andreatta M, Ortiz-Miranda Y, Muller T, et al.
Nat Immunol
. 2023 Apr;
24(5):869-883.
PMID: 37081150
To date, no immunotherapy approaches have managed to fully overcome T-cell exhaustion, which remains a mandatory fate for chronically activated effector cells and a major therapeutic challenge. Understanding how to...
3.
Irving M, Lanitis E, Migliorini D, Ivics Z, Guedan S
Hum Gene Ther
. 2021 Oct;
32(19-20):1044-1058.
PMID: 34662233
T cell modification with genes that encode chimeric antigen receptors (CAR-T cells) has shown tremendous promise for the treatment of B cell malignancies. The successful translation of CAR-T cell therapy...
4.
Lanitis E, Kosti P, Ronet C, Cribioli E, Rota G, Spill A, et al.
J Immunother Cancer
. 2021 Aug;
9(8).
PMID: 34389616
Background: The adoptive transfer of chimeric antigen receptor (CAR)-T cells has emerged as a potent immunotherapy against some hematological malignancies but not yet for epithelial-derived solid tumors. One critical issue...
5.
Bruand M, Barras D, Mina M, Ghisoni E, Morotti M, Lanitis E, et al.
Cell Rep
. 2021 Jul;
36(3):109412.
PMID: 34289354
In this study, we investigate mechanisms leading to inflammation and immunoreactivity in ovarian tumors with homologous recombination deficiency (HRD). BRCA1 loss is found to lead to transcriptional reprogramming in tumor...
6.
Lanitis E, Rota G, Kosti P, Ronet C, Spill A, Seijo B, et al.
J Exp Med
. 2020 Nov;
218(2).
PMID: 33156338
Limited clinical benefit has been demonstrated for chimeric antigen receptor (CAR) therapy of solid tumors, but coengineering strategies to generate so-called fourth-generation (4G) CAR-T cells are advancing toward overcoming barriers...
7.
Lanitis E, Coukos G, Irving M
Curr Opin Biotechnol
. 2020 Feb;
65:75-87.
PMID: 32109718
Synthetic biology has been transformative to the treatment of advanced hematological malignancies by chimeric antigen receptor (CAR)-engineered T cells. A range of obstacles are now understood to limit the responses...
8.
Monnot G, Martinez-Usatorre A, Lanitis E, Ferreira Lopes S, Cheng W, Ho P, et al.
Mol Ther Oncolytics
. 2020 Feb;
16:111-123.
PMID: 32021906
Therapy by adoptive transfer of -expanded tumor-infiltrating or genetically modified T cells may lead to impressive clinical responses. However, there is a need to improve persistence and functionality of the...
9.
Dangaj D, Bruand M, Grimm A, Ronet C, Barras D, Duttagupta P, et al.
Cancer Cell
. 2019 Jun;
35(6):885-900.e10.
PMID: 31185212
We investigated the role of chemokines in regulating T cell accumulation in solid tumors. CCL5 and CXCL9 overexpression was associated with CD8 T cell infiltration in solid tumors. T cell...
10.
Tschumi B, Dumauthioz N, Marti B, Zhang L, Lanitis E, Irving M, et al.
J Immunother Cancer
. 2018 Sep;
6(1):92.
PMID: 30253808
After publication of this article [1], it was noticed that 3 authors were missed from the author list.